| |
| |
|
| Insider
Information: |
Topper James N |
| Relationship: |
|
| City: |
Seattle |
| State: |
WA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
14 |
|
| Direct
Shares |
20,715,944 |
|
|
Indirect Shares
|
33,777,420 |
|
|
| Direct
Value |
$195,395,319 |
|
|
|
Indirect Value
|
$517,185,955 |
|
|
| Total
Shares |
54,493,364 |
|
|
| Total
Value |
$712,581,273 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
3
|
1
|
|
Stock
price went up :
|
0
|
1
|
| Stock
price went down : |
3
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
-3.0
|
1.0
|
| Percentage
Gain/Loss : |
 -17.1%
|
 0.5%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
La Jolla Pharmaceutical Co |
LJPC |
Director |
2005-12-14 |
0 |
2009-02-26 |
0 |
Premium* |
|
|
Amicus Therapeutics Inc |
FOLD |
Director, 10% Owner |
2007-06-05 |
0 |
2008-03-10 |
3,520,678 |
Premium* |
|
|
Portola Pharmaceuticals Inc |
PTLA |
Director |
2013-05-28 |
0 |
2013-05-28 |
1,428,954 |
Premium* |
|
|
Sierra Oncology Inc |
SRRA |
Director, 10% Owner |
2015-07-21 |
0 |
2017-02-14 |
8,112,121 |
Premium* |
|
|
Anaptysbio Inc |
ANAB |
Director |
2020-11-16 |
80,812 |
2020-11-16 |
199,529 |
Premium* |
|
|
Alpine Immune Sciences Inc |
ALPN |
Director |
2022-02-11 |
1,484,115 |
2024-05-18 |
0 |
Premium* |
|
|
Allena Pharmaceuticals, Inc. |
ALNA |
Director, 10% Owner |
2017-11-06 |
0 |
2017-11-06 |
3,330,373 |
Premium* |
|
|
Aptinyx Inc. |
APTX |
Director |
2018-06-25 |
0 |
2020-03-31 |
3,195,055 |
Premium* |
|
|
Entasis Therapeutics Holdings Inc. |
ETTX |
Director, 10% Owner |
2018-09-28 |
0 |
2018-09-28 |
1,349,953 |
Premium* |
|
|
Mirum Pharmaceuticals, Inc. |
MIRM |
10% Owner |
2019-07-22 |
3,566,912 |
2019-07-22 |
0 |
Premium* |
|
|
Arcutis Biotherapeutics, Inc. |
ARQT |
10% Owner |
2020-02-04 |
10,542,790 |
|
0 |
Premium* |
|
|
Passage Bio, Inc. |
PASG |
10% Owner |
2020-03-03 |
5,009,219 |
2020-03-03 |
0 |
Premium* |
|
|
Phathom Pharmaceuticals, Inc. |
PHAT |
|
2024-05-23 |
32,096 |
2024-05-23 |
5,831,328 |
Premium* |
|
|
Newamsterdam Pharma Ord Shs |
NAMS |
|
|
0 |
2024-03-26 |
6,809,429 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
95 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2008-02-26 |
4 |
B |
$9.99 |
$19,323 |
I/I |
1,900 |
727,681 |
2.17 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2008-02-27 |
4 |
B |
$9.65 |
$143,616 |
I/I |
14,700 |
742,381 |
2.25 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2008-02-27 |
4 |
B |
$9.95 |
$86,480 |
I/I |
8,600 |
750,981 |
2.25 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2008-02-28 |
4 |
B |
$9.84 |
$20,195 |
I/I |
2,038 |
753,019 |
2.17 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2008-02-28 |
4 |
B |
$9.97 |
$58,068 |
I/I |
5,762 |
758,781 |
2.25 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2008-02-29 |
4 |
B |
$9.63 |
$85,356 |
I/I |
8,637 |
767,418 |
2.25 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2008-03-03 |
4 |
B |
$9.51 |
$422,230 |
I/I |
43,674 |
811,092 |
2.25 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2008-03-03 |
4 |
B |
$9.83 |
$24,720,612 |
I/I |
18,426 |
829,518 |
2.25 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2008-03-04 |
4 |
B |
$9.60 |
$43,719 |
I/I |
4,500 |
834,018 |
2.25 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2008-03-04 |
4 |
B |
$9.85 |
$89,869 |
I/I |
9,000 |
843,018 |
2.25 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2008-03-05 |
4 |
B |
$9.64 |
$116,133 |
I/I |
12,008 |
855,026 |
2.25 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2008-03-05 |
4 |
B |
$9.76 |
$371,681 |
I/I |
37,992 |
893,018 |
2.25 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2008-03-06 |
4 |
B |
$9.90 |
$221,723 |
I/I |
22,146 |
915,164 |
2.25 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2008-03-10 |
4 |
B |
$9.98 |
$7,651 |
I/I |
760 |
915,924 |
2.17 |
- |
|
| FOLD |
Amicus Therapeutics Inc |
Director |
– • • |
2008-03-10 |
4 |
B |
$10.19 |
$48,696 |
I/I |
4,740 |
920,664 |
2.25 |
- |
|
| ETTX |
Entasis Therapeutics Hold... |
Director |
– • • |
2018-09-28 |
4 |
A |
$0.00 |
$0 |
I/I |
910,092 |
974,066 |
0 |
- |
|
| ETTX |
Entasis Therapeutics Hold... |
Director |
– • • |
2018-09-28 |
4 |
B |
$15.00 |
$5,638,305 |
I/I |
375,887 |
1,349,953 |
2.25 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
Director |
– • – |
2013-05-28 |
4 |
A |
$0.00 |
$0 |
I/I |
1,436,206 |
1,428,954 |
0 |
- |
|
| ALPN |
Alpine Immune Sciences In... |
Director |
– • • |
2022-02-11 |
4 |
B |
$7.10 |
$799,989 |
D/D |
112,665 |
1,484,115 |
3.92 |
% |
|
| ALPN |
Alpine Immune Sciences In... |
Director |
– • – |
2023-12-11 |
4 |
OE |
$12.74 |
$1,850,498 |
I/I |
145,251 |
1,629,366 |
0 |
- |
|
| SRRA |
Sierra Oncology Inc |
Director |
– • – |
2015-07-21 |
4 |
A |
$0.00 |
$0 |
I/I |
1,869,606 |
1,869,606 |
0 |
- |
|
| SRRA |
Sierra Oncology Inc |
Director |
– • – |
2015-07-21 |
4 |
A |
$5.22 |
$503,712 |
I/I |
96,589 |
1,966,195 |
0 |
- |
|
| SRRA |
Sierra Oncology Inc |
Director |
– • – |
2015-07-21 |
4 |
B |
$17.00 |
$3,740,000 |
I/I |
220,000 |
2,186,195 |
2.1 |
- |
|
| ALPN |
Alpine Immune Sciences In... |
Director |
– • • |
2017-07-24 |
4 |
A |
$0.00 |
$0 |
I/I |
2,199,011 |
2,199,011 |
0 |
- |
|
| ALPN |
Alpine Immune Sciences In... |
Director |
– • • |
2019-01-18 |
4 |
B |
$5.37 |
$1,999,997 |
I/I |
372,439 |
2,571,450 |
2.25 |
- |
|
95 Records found
|
|
Page 3 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
